GOSSAMER BIO, INC. Operating Cash Flow
GOSSAMER BIO, INC. (GOSS) reported Operating Cash Flow of -$78.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$39.42M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$38.72M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$48.31M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$36.17M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$171.27M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$3.47M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$159.16M.
- GOSSAMER BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$187.03M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$78.14M 10-Q · filed 2026-08-13 | -$126.46M derived: sum of 3 quarters · filed 2026-08-13 | -$162.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$38.72M 10-Q · filed 2026-05-15 | -$87.03M derived: sum of 2 quarters · filed 2026-05-15 | -$123.20M derived: sum of 3 quarters · filed 2026-05-15 | -$170.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$48.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$84.48M derived: sum of 2 quarters · filed 2026-03-17 | -$131.54M derived: sum of 3 quarters · filed 2026-08-13 | -$171.27M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$36.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$83.23M derived: sum of 2 quarters · filed 2026-08-13 | -$122.95M 10-Q · filed 2025-11-05 | -$158.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$47.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$86.78M 10-Q · filed 2026-08-13 | -$122.27M derived: sum of 3 quarters · filed 2026-08-13 | -$154.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$39.72M 10-Q · filed 2026-05-15 | -$75.20M derived: sum of 2 quarters · filed 2026-05-15 | -$107.24M derived: sum of 3 quarters · filed 2026-05-15 | $9.11M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$35.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$67.51M derived: sum of 2 quarters · filed 2026-03-17 | $48.83M derived: sum of 3 quarters · filed 2026-03-17 | -$3.47M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$32.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $84.31M derived: sum of 2 quarters · filed 2025-11-05 | $32.01M 10-Q · filed 2025-11-05 | -$1.41M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $116.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $64.05M 10-Q · filed 2025-08-05 | $30.62M derived: sum of 3 quarters · filed 2026-03-17 | -$3.87M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$52.30M 10-Q · filed 2025-05-15 | -$85.73M derived: sum of 2 quarters · filed 2026-03-17 | -$120.22M derived: sum of 3 quarters · filed 2026-03-17 | -$158.47M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$33.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$67.92M derived: sum of 2 quarters · filed 2026-03-17 | -$106.17M derived: sum of 3 quarters · filed 2026-03-17 | -$159.16M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$34.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$72.75M derived: sum of 2 quarters · filed 2024-11-07 | -$125.73M 10-Q · filed 2024-11-07 | -$173.46M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$38.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$91.24M 10-Q · filed 2024-08-12 | -$138.97M derived: sum of 3 quarters · filed 2025-03-13 | -$175.97M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$52.99M 10-Q · filed 2024-05-07 | -$100.72M derived: sum of 2 quarters · filed 2025-03-13 | -$137.72M derived: sum of 3 quarters · filed 2025-03-13 | -$186.54M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$47.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$84.73M derived: sum of 2 quarters · filed 2025-03-13 | -$133.55M derived: sum of 3 quarters · filed 2025-03-13 | -$187.03M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$85.82M derived: sum of 2 quarters · filed 2023-11-09 | -$139.30M 10-Q · filed 2023-11-09 | -$179.81M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$48.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$102.31M 10-Q · filed 2023-08-08 | -$142.81M derived: sum of 3 quarters · filed 2024-03-05 | -$184.85M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$53.48M 10-Q · filed 2023-05-09 | -$93.99M derived: sum of 2 quarters · filed 2024-03-05 | -$136.03M derived: sum of 3 quarters · filed 2024-03-05 | -$183.48M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$40.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$82.54M derived: sum of 2 quarters · filed 2024-03-05 | -$129.99M derived: sum of 3 quarters · filed 2024-03-05 | -$188.89M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$42.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$89.48M derived: sum of 2 quarters · filed 2022-11-03 | -$148.38M 10-Q · filed 2022-11-03 | -$185.12M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | -$47.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$106.35M 10-Q · filed 2022-08-09 | -$143.08M derived: sum of 3 quarters · filed 2023-03-17 | -$188.01M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | -$58.90M 10-Q · filed 2022-05-10 | -$95.63M derived: sum of 2 quarters · filed 2023-03-17 | -$140.56M derived: sum of 3 quarters · filed 2023-03-17 | -$182.96M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | -$36.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$81.67M derived: sum of 2 quarters · filed 2023-03-17 | -$124.06M derived: sum of 3 quarters · filed 2023-03-17 | -$176.36M 10-K · filed 2023-03-17 |
| 2020-09-30 | -$44.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$87.33M derived: sum of 2 quarters · filed 2021-11-08 | -$139.62M 10-Q · filed 2021-11-08 | -$183.76M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | -$42.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$94.69M 10-Q · filed 2021-08-09 | -$138.83M derived: sum of 3 quarters · filed 2022-03-03 | -$174.94M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | -$52.30M 10-Q · filed 2021-05-06 | -$96.44M derived: sum of 2 quarters · filed 2022-03-03 | -$132.54M derived: sum of 3 quarters · filed 2022-03-03 | -$169.35M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | -$44.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$80.25M derived: sum of 2 quarters · filed 2022-03-03 | -$117.06M derived: sum of 3 quarters · filed 2022-03-03 | -$144.83M 10-K · filed 2022-03-03 |
| 2019-09-30 | -$36.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$72.92M derived: sum of 2 quarters · filed 2020-11-10 | -$100.69M 10-Q · filed 2020-11-10 | -$125.72M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$36.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$64.58M 10-Q · filed 2020-08-11 | -$89.61M derived: sum of 3 quarters · filed 2021-02-26 | -$105.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$27.77M 10-Q · filed 2020-05-12 | -$52.80M derived: sum of 2 quarters · filed 2021-02-26 | -$68.31M derived: sum of 3 quarters · filed 2021-02-26 | -$75.11M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$25.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$40.54M derived: sum of 2 quarters · filed 2021-02-26 | -$47.34M derived: sum of 3 quarters · filed 2021-02-26 | -$51.04M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$15.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$22.31M derived: sum of 2 quarters · filed 2019-11-12 | -$26.02M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$10.51M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$3.71M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | -$5.75M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |